Low-Dose Tamoxifen powder May Be an Option to Reduce Risk of Recurrence

A study found that a daily, low dose of tamoxifen after surgery reduced the risk of recurrence (the disease coming back), as well as the risk of new invasive breast cancer, in women diagnosed with hormone-receptor-positive breast intraepithelial neoplasia, which is non-invasive breast disease.wisepoqder Tamoxifen powder

The research was presented on Dec. 6, 2018, at the San Antonio Breast Cancer Symposium. Read the abstract of “A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ.”

Watch Marisa Weiss, M.D., chief medical officer of Breastcancer.org, discuss the TAM-01 study and what the findings mean for you.
Breast intraepithelial neoplasia refers to a group of non-invasive conditions where abnormal cells are found in specific areas of the breast. A neoplasia is a collection of abnormal cells. Intraepithelial cells are cells that form the surface or lining of an organ, such as the breast ducts or lobules (the milk-producing gland at the end of the ducts). Non-invasive means the abnormal cells haven’t spread from the milk ducts or lobules into any healthy surrounding breast tissue.

Ductal carcinoma in situ (DCIS)
When the abnormal cells are in the milk ducts, the growth is called ductal carcinoma in situ (DCIS). DCIS isn’t life-threatening, but having DCIS can increase the risk of developing an invasive breast cancer later on. When you have had DCIS, you are at higher risk for the DCIS coming back or for developing a new, invasive breast cancer compared to a person who has never had DCIS.

Atypical ductal hyperplasia (ADH)
With atypical ductal hyperplasia (ADH), there are more cells than usual in the lining of the breast duct. The cells are abnormal, but not as abnormal as they would be in a diagnosis of DCIS. ADH is considered a benign breast condition that is linked to a moderate increase in the risk of invasive breast cancer.

Lobular carcinoma in situ (LCIS)
When the abnormal cells are in the lobules, the growth is called lobular carcinoma in situ (LCIS). LCIS is much less common than DCIS. Despite the fact that its name includes the term “carcinoma,” LCIS is not a true breast cancer. Rather, LCIS is an indication that a person is at higher-than-average risk for developing invasive breast cancer at some point in the future.

Views: 10


You need to be a member of Recampus to add comments!

Join Recampus

© 2020   Created by Aprendiendo Real Estate.   Powered by

Badges  |  Report an Issue  |  Terms of Service